A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
OncoResponse, Inc.
Novartis
Memorial Sloan Kettering Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC